| Page 30 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study

Author(s): 
Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S
Primary Author: 
Mitani K
Journal Title: 
Blood Advances
Original Publication Date: 
Dec 2023
Bone Marrow Disease(s): 

Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study

Author(s): 
Fattizzo B, Gurnari C, Cassanello G, Bortolotti M, Awada H, Giammarco S, Consonni D, Sica S, Gandhi S, Trikha R, Large J, Salter S, Maciejewski JP, Barcellini W, Kulasekararaj AG
Primary Author: 
Fattizzo B
Journal Title: 
Leukemia
Original Publication Date: 
Dec 2023

Non-severe

Bone Marrow Disease(s): 

Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis

Author(s): 
Lee J, Lee H, Kim S, Suh HS
Primary Author: 
Lee J
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
Dec 2023

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematological disease. The development of complement inhibitors such as eculizumab, ravulizumab, and pegcetacoplan has revolutionized the management of PNH, leading to improvements in overall survival and quality of life for patients.

Bone Marrow Disease(s): 

Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia

Author(s): 
de Latour RP, Kulasekararaj A, Iacobelli S, Griffin M, Halkes CJ, Dufour C, Risitano AM
Primary Author: 
de Latour RP
Journal Title: 
Immunotherapy
Original Publication Date: 
Dec 2023

What is this summary about?: Severe

Bone Marrow Disease(s):